Patents by Inventor Jeffrey O'Meara
Jeffrey O'Meara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8198458Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.Type: GrantFiled: February 3, 2009Date of Patent: June 12, 2012Assignee: Boehringer Ingelheim International GmbHInventors: Patrick DeRoy, Anne-Marie Faucher, Alexandre Gagnon, Serge R. Landry, Sebastien Morin, Jeffrey O'Meara, Bruno Simoneau, Bounkham Thavonekham, Christiane Yoakim
-
Publication number: 20120077737Abstract: Compounds of the invention, which are macrocyclic peptide analogs containing an acylsulfonamide moiety, maintain good activity against NS3 proteases containing clinically relevant resistance mutations for this class as represented by genotype 1a R155K, genotype 1b D168V and genotype 1a D168V resistance mutations. The compounds of the invention are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: November 23, 2010Publication date: March 29, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse Llinas-Brunet, Josée Bordeleau, Cédrickx Godbout, Mélissa Leblanc, Benoît Moreau, Jeffrey O'Meara
-
Publication number: 20110294778Abstract: Compounds of Formula (I) wherein R1, R2, R3, R4 and R5 are defined herein, maintain good activity against NS3 proteases containing clinically relevant genotype 1a R155K and genotype 1b D168V resistance mutations. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.Type: ApplicationFiled: November 23, 2010Publication date: December 1, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Josée BORDELEAU, Cédrickx GODBOUT, Mélissa LEBLANC, Benoît MOREAU, Jeffrey O'MEARA
-
Patent number: 7807670Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A,; X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.Type: GrantFiled: November 13, 2008Date of Patent: October 5, 2010Assignee: Boehringer Ingelheim Canada Ltd.Inventors: Christiane Yoakim, Bruno Hache, William W. Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
-
Publication number: 20100087382Abstract: Compounds of formula I: wherein R1, R2, R2a, R3, R4 and R5 are defined herein, are useful as inhibitors of the HCV NS3 protease.Type: ApplicationFiled: February 15, 2008Publication date: April 8, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Murray D. Bailey, Francois Bilodeau, Pasquale Forgione, Vida Gorys, Montse Llinas-Brunet, Julie Naud, Jeffrey O'Meara, Marc-Andre Poupart
-
Publication number: 20100041649Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A, X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.Type: ApplicationFiled: November 13, 2008Publication date: February 18, 2010Inventors: Christiane Yoakim, Bruno Hache, William W. Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
-
Patent number: 7642277Abstract: Disclosed herein are compounds of formula Ar1—X—W—Ar2 wherein Ar1 and Ar2 represent aryl groups characterized generally as aromatic heterocycles (e.g. imidazolyl or tetrazolyl) or carbocycles (e.g. phenyl or naphthalenyl); the aryl groups are optionally substituted or fused with other heterocycles or carbocycles; the aryl groups can bear substituents such as alkyl, halo or O-alkyl. X is a heteroatom, a valence bond or an optionally substituted divalent methylene, and W represents a spacer; typical spacers include divalent alkylene or alkylene-amido, -amido or -oxy radicals, which may optionally be substituted (e.g. hydroxyl or oxo). A typical compound is a derivative of 2-(N-napthalenyltetrazolylthio)-N-(2-nitrophenyl)acetamide. The compounds have inhibitory activity against Wild Type and single or double mutant strains of HIV.Type: GrantFiled: November 21, 2003Date of Patent: January 5, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Anne-Marie Faucher, Serge Landry, Jeffrey O'Meara, Bounkham Thavonekham, Christiane Yoakim
-
Patent number: 7569723Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against HIV. In particular, the compounds are active against wild type and single or double mutant strains of HIV.Type: GrantFiled: January 15, 2008Date of Patent: August 4, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Jeffrey O'Meara, Christiane Yoakim
-
Publication number: 20090143370Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.Type: ApplicationFiled: February 3, 2009Publication date: June 4, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Patrick DeROY, Anne-Marie FAUCHER, Alexandre GAGNON, Serge LANDRY, Sebastien MORIN, Jeffrey O'MEARA, Bruno SIMONEAU, Bounkham THAVONEKHAM, Christiane YOAKIM
-
Patent number: 7528167Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A, X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.Type: GrantFiled: May 12, 2006Date of Patent: May 5, 2009Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Christiane Yoakim, William W. Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
-
Patent number: 7517998Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.Type: GrantFiled: May 24, 2005Date of Patent: April 14, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Patrick Deroy, Anne-Marie Faucher, Alexandre Gagnon, Serge Landry, Sebastien Morin, Jeffrey O'Meara, Bruno Simoneau, Bounkham Thavonekham, Christiane Yoakim
-
Publication number: 20080114068Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against HIV. In particular, the compounds are active against wild type and single or double mutant strains of HIV.Type: ApplicationFiled: January 15, 2008Publication date: May 15, 2008Applicant: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Jeffrey O'Meara, Christiane Yoakim
-
Patent number: 7300948Abstract: Inhibitors of HIV reverse transcriptase which are useful for the treatment of HIV infection. Exemplars of the invention are compounds of the formula wherein the substituents are as defined in the following table R1 R2 R4 R5 R8a F CF3 Me H —OH F CF3 Cl H —OH F CF3 Me H —O—CH2CO2H Cl CN Cl H —OH.Type: GrantFiled: September 29, 2005Date of Patent: November 27, 2007Assignee: Boehringer Ingelheim International GmbHInventors: Pierre Bonneau, Patrick Deroy, Alexandre Gagnon, Jeffrey O′Meara, Bruno Simoneau, Christiane Yoakim
-
Patent number: 7273861Abstract: Compounds represented by formula 1: wherein R1 is H, halogen, (C1-4)alkyl, O(C1-4)alkyl, and haloalkyl; R2 is H or methyl; R3 is H or (C1-4)alkyl; R4 is H or (C1-4)alkyl; R5 is (C1-4)alkyl, (C1-4)alkyl(C3-7)cyclo-alkyl or (C3-7)cycloalkyl; and W is a fused phenyl-5 or 6-membered heterocycle having one or two heteroatoms selected from N or S; or W is phenyl, 1,1?-biphenyl, 2,3-dihydro-1H-indene, 1,2,3,4-tetrahydronaphthyl, or naphthyl; said W being optionally substituted with (C1-4)alkyl, which in turn can be optionally substituted with a carboxy or (C1-4)alkoxycarbonyl, or a salt or ester thereof. The compounds have inhibitory activity against Wild Type, single and double mutant strains of HIV.Type: GrantFiled: September 15, 2003Date of Patent: September 25, 2007Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Christiane Yoakim, Jeffrey O'Meara, Bruno Simoneau, William Ogilvie, Robert Déziel
-
Publication number: 20060235010Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A, X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.Type: ApplicationFiled: May 12, 2006Publication date: October 19, 2006Applicant: Boehringer Ingelheim (Canada) Ltd.Inventors: Christiane Yoakim, William Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
-
Patent number: 7119099Abstract: A compound of formula (I) or its enantiomers or diastereoisomers thereof: wherein: A,; X, W, R1, Y; R3; and R4 are as defined herein. The compounds of the invention may be used as inhibitors of the papilloma virus E1-E2-DNA complex. The invention further provides a method of treating or preventing human papilloma virus infection.Type: GrantFiled: February 4, 2004Date of Patent: October 10, 2006Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Christiane Yoakim, William W. Ogilvie, Jeffrey O'Meara, Peter White, Nathalie Goudreau
-
Publication number: 20060069261Abstract: Inhibitors of HIV reverse transcriptase which are useful for the treatment of HIV infection. Exemplars of the invention are compounds of the formula wherein the substituents are as defined in the following table.Type: ApplicationFiled: September 29, 2005Publication date: March 30, 2006Applicant: Boehringer Ingelheim International GmbHInventors: Pierre Bonneau, Patrick Deroy, Alexandre Gagnon, Jeffrey O'Meara, Bruno Simoneau, Christiane Yoakim
-
Publication number: 20060025480Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against HIV. In particular, the compounds are active against wild type and single or double mutant strains of HIV.Type: ApplicationFiled: July 19, 2005Publication date: February 2, 2006Applicant: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Jeffrey O'Meara, Christiane Yoakim
-
Publication number: 20050282907Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.Type: ApplicationFiled: May 24, 2005Publication date: December 22, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Patrick Deroy, Anne-Marie Faucher, Alexandre Gagnon, Serge Landry, Sebastien Morin, Jeffrey O'Meara, Bruno Simoneau, Bounkham Thavonekham, Christiane Yoakim
-
Publication number: 20050054639Abstract: Disclosed herein are compounds of formula Ar1—X—W—Ar2 wherein Ar1 and Ar2 represent aryl groups characterized generally as aromatic heterocycles (e.g. imidazolyl or tetrazolyl) or carbocycles (e.g. phenyl or naphthalenyl); the aryl groups are optionally substituted or fused with other heterocycles or carbocycles; the aryl groups can bear substituents such as alkyl, halo or O-alkyl. X is a heteroatom, a valence bond or an optionally substituted divalent methylene, and W represents a spacer; typical spacers include divalent alkylene or alkylene-amido, -amido or -oxy radicals, which may optionally be substituted (e.g. hydroxyl or oxo). A typical compound is a derivative of 2-(N-napthalenyltetrazolylthio)-N-(2-nitrophenyl)acetamide. The compounds have inhibitory activity against Wild Type and single or double mutant strains of HIV.Type: ApplicationFiled: November 21, 2003Publication date: March 10, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Anne-Marie Faucher, Serge Landry, Jeffrey O'Meara, Bounkham Thavonekham, Christiane Yoakim